WORLDWIDE REGISTRATION
Cabotegravir PrEP

APPROVAL

United States
Australia
Zimbabwe
South Africa
Malawi
Botswana
Brazil
Philippines
Zambia
European Medicines Agency (EMA)
Malaysia
Peru
Nigeria
Thailand

SUBMISSION

Kenya
Uganda
Vietnam
Myanmar
China
Ukraine
Namibia

Colombia
United Kingdom
Ivory Coast
Mozambique
Rwanda
Tanzania
Canada

✓ “Approval” means: Marketing Authorisation has been granted by a country or there is no formal regulatory process in place, in the relevant country.
✓ Granted Marketing Authorisations may include limitations on the use of the product.

This document was prepared on 18 January 2024 and will be updated on a quarterly basis by Viiv Healthcare. It is made available for information purposes only and Viiv Healthcare accepts no liability arising from the reliance by third parties, on the information provided.